Pfizer Inc. (PFE)
Ahead of Pfizer (PFE) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Get a deeper insight into the potential performance of Pfizer (PFE) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Pfizer: A High-Yield Pharma At A Turning Point
Pfizer remains in the 'green zone' in 2026 despite retail investors' pessimism over the approaching LOE cycle. I believe retail investors' fears about the end of exclusivity for Pfizer's blockbusters, such as Xeljanz and Ibrance, in 2026-2028, are overblown. This is because Pfizer has a strong pipeline of FDA-approved cancer drugs and vaccines, as well as potentially best-in-class GLP-1/amylin-based therapies, MET-097i/MET-233i.
Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider
Pfizer (PFE) reached $26.5 at the closing of the latest trading day, reflecting a +2.4% change compared to its last close.
Earnings Preview: Pfizer (PFE) Q4 Earnings Expected to Decline
Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pfizer vs. Merck Stock And JNJ
In the last six months Pfizer's stock (NYSE: PFE) has underperformed Merck (NYSE: MRK) and Johnson & Johnson (NYSE: JNJ) primarily due to waning demand for its COVID-19 products, a significant upcoming patent cliff, and a lukewarm financial outlook for 2026.
Pfizer: The Great Healthcare Plan Does Not Change My Bullish Stance
The Great Healthcare Plan has threatened the biopharma sector with mandatory global price parity, but the market is overlooking a critical carve-out specific to Pfizer. While competitors face immediate tariff risks, Pfizer's negotiated 3-year exemption from Section 232 and the potential dismantling of the PBM rebate model create an underappreciated margin defense. I explain why the launch of TrumpRx.gov is a volume opportunity rather than a revenue threat, reinforcing my bullish thesis despite the headline regulatory noise.
Pfizer: Expect Another Double Beating For Q1 (Earnings Preview)
Pfizer (PFE) remains a 'Buy' ahead of its fiscal Q1 2027 earnings, with the stock deeply discounted and consensus estimates overly pessimistic. LOE headwinds are significant but phased, while cost savings ($7.7B by 2027) and pipeline catalysts offer margin and revenue offsets. Pipeline momentum—especially in obesity, oncology, and vaccines—could drive narrative shifts and repricing if key 2026 readouts succeed.
Pfizer (PFE) Outperforms Broader Market: What You Need to Know
Pfizer (PFE) closed the most recent trading day at $25.9, moving +1.49% from the previous trading session.
MoneyShow's Best Investment Ideas For 2026: Part 7
MoneyShow presents top investment ideas for 2026 from their contributors. This year's edition presents a mix of metals plays, financial stocks, deep value names, high-octane growth and tech stocks, and beaten-down REITs that offer solid income and turnaround potential. Part 7 of this series includes Pfizer, Philip Morris International, Platinum Group Metals, Prologis and QuickLogic Corp.
What to Expect From Pfizer's Non-Oncology Business in Q4?
PFE's Q4 outlook centers on Eliquis growth, softer COVID-19 sales and steady demand for key non-oncology drugs ahead of earnings.
Pfizer: Rebound Has Just Started
Pfizer has outperformed the S&P 500 since my previous call, driven by improving fundamentals and renewed share price momentum. Positive developments around the pipeline support long-term financial stability, reinforcing confidence in PFE's outlook. PFE's substantial 6.7% forward dividend yield appears secure, offering attractive income in a volatile market.
Pfizer: The Most Intriguing Value Play Of 2026
Pfizer remains a Strong Buy, with oncology breakthroughs, a revitalized obesity pipeline, and aggressive cost savings supporting a compelling value thesis. BRAFTOVI's Phase 3 success and PADCEV + Keytruda's expanded indications position PFE for blockbuster growth in precision oncology. The obesity pipeline, including MET-097i and a new oral candidate, could catalyze a major re-rating if Phase 3 data are positive.
